UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-08, Vol.377 (9), p.829-838

2017

Volltextzugriff (PDF)

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Annals of oncology, 2020-02, Vol.31 (2), p.310-317

2020

Volltextzugriff (PDF)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

The Lancet (British edition), 2013-03, Vol.381 (9869), p.805-816

2013

Volltextzugriff (PDF)

Safety and Efficacy of Necitumumab (N) During Single-Agent Treatment to Progression Following Gemcitabine-Cisplatin (GC) Chemotherapy Plus Necitumumab (IMC-11F8/LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (sq-NSCLC) (SQUIRE)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S31-S32

2014

Volltextzugriff (PDF)

TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S35-S35

2014

Volltextzugriff (PDF)

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S7-S8

2019

Volltextzugriff (PDF)

Safety and Efficacy of Necitumumab (N) During Single-Agent Treatment to Progression Following Gemcitabine-Cisplatin (GC) Chemotherapy Plus Necitumumab (IMC-11F8/LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (sq-NSCLC) (SQUIRE): Metastatic Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S31-S32

2014

Volltextzugriff (PDF)

TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results: Metastatic Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S35-S35

2014

Volltextzugriff (PDF)

Time, a Phase 2B/3 Study Evaluating Tg4010 in Combination with First Line Therapy in Advanced Non Small Cell Lung Cancer (Nsclc). Phase 2B Results

Annals of oncology, 2014-09, Vol.25, p.iv364

2014

Volltextzugriff (PDF)

A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.7001-7001

2011

Volltextzugriff (PDF)

IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)

Annals of oncology, 2018-12, Vol.29, p.x17-x17

2018

Volltextzugriff (PDF)

Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study: PL02.11

Journal of thoracic oncology, 2019-10, Vol.14 (10 Suppl), p.S7-S8

2019

Volltextzugriff (PDF)

Why they want to be treated in clinical trial -fundamental reasons of patient's decision

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.6147-6147

2004

Volltextzugriff (PDF)

Why they want to be treated in clinical trial -fundamental reasons of patient's decision

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.6147-6147

2004

Volltextzugriff (PDF)

1055PDTIME, A PHASE 2B/3 STUDY EVALUATING TG4010 IN COMBINATION WITH FIRST LINE THERAPY IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC). PHASE 2B RESULTS

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv364-iv364

2014

Volltextzugriff (PDF)

918 The role of patients and doctors in making decisions about the choice of the kind of adjuvant treatment in early breast cancer

European journal of cancer supplements, 2003-09, Vol.1 (5), p.S276-S276

2003

Volltextzugriff (PDF)

49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)

Annals of oncology, 2018-12, Vol.29 (suppl_10)

2018

Volltextzugriff (PDF)

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2014-09, Vol.85 (3), p.420-428

2014

Volltextzugriff (PDF)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Annals of oncology, 2016-03, Vol.27 (3), p.417-423

2016

Volltextzugriff (PDF)

Abstract PD1-04: Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane chemotherapy in metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD1-04-PD1-04

2020

Volltextzugriff (PDF)

Safety and efficacy of necitumumab continuation therapy: Subgroup analysis of phase 3 SQUIRE study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e19024-e19024

2015

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(36)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Humans
(10)
Middle Aged
(9)
Oncology
(9)
Female
(8)
Male
(8)
Lung Neoplasms - Drug Therapy
(7)
Aged
(6)
Cancer Therapies
(6)
Hematology, Oncology And Palliative Medicine
(6)
Adult
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Chemotherapy
(5)
Disease-Free Survival
(5)
Lung Cancer
(5)
Treatment Outcome
(5)
Tumors
(5)
Aged, 80 And Over
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Safety and Efficacy of Necitumumab (N) During Single-Agent Treatment to Progression Following Gemcitabine-Cisplatin (GC) Chemotherapy Plus Necitumumab (IMC-11F8/LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (sq-NSCLC) (SQUIRE)

TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results: Metastatic Non-Small Cell Lung Cancer

Time, a Phase 2B/3 Study Evaluating Tg4010 in Combination with First Line Therapy in Advanced Non Small Cell Lung Cancer (Nsclc). Phase 2B Results

A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC)

IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)

Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study: PL02.11

Why they want to be treated in clinical trial -fundamental reasons of patient's decision

Why they want to be treated in clinical trial -fundamental reasons of patient's decision

1055PDTIME, A PHASE 2B/3 STUDY EVALUATING TG4010 IN COMBINATION WITH FIRST LINE THERAPY IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC). PHASE 2B RESULTS

918 The role of patients and doctors in making decisions about the choice of the kind of adjuvant treatment in early breast cancer

49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Abstract PD1-04: Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane chemotherapy in metastatic breast cancer (MBC)

Safety and efficacy of necitumumab continuation therapy: Subgroup analysis of phase 3 SQUIRE study

Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma

Suchergebnisse filtern